References
- Aberle DR, Adams AM, Berg CD, et al.. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
- Preventive Services Task Force. Screening for lung cancer. 2013. Available from: http://www.uspreventiveservicestaskforce.org/uspstf/uspslung.hetm
- Kissinger LS, Anderson C, Kim J, et al. Implementation of lung cancer screening in the veterans health administration. JAMA Intern Med. 2016. DOI:10.1001/jamainternmed.2016.9022.
- Veronesi G, Maisonneuve P, Bellomi M, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2012;157:76–784.
- Gould MK. Lung-cancer screening with low-dose computed tomography. N Engl J Med. 2014;37:1:1813–1820.
- Wiener RS, Schwartz LM, Woloshin S, et al. Population based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med. 2011;155(3):137–144.
- Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. The WHO committee on histiocytic/reticulum cell proliferations. Reclassification working group of the histiocytic society. Med Pediatr Oncol. 1997;29:157–166.
- Elia D, Torre O, Cassandro R, et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med. 2015;26:351–356.
- Jaffe R, Weiss LM, Facchetti F. Tumours derived from Langerhans cells. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classificaiton of tumors of the mematopoietic and lymphoid tissues. 4th ed. Lyon:IARC Pres; 2008. p.358–360.
- Etienne B, Berocchi M, Gamondes JP, et al. Relapsing pulmonary Langerhans cell histiocytosis after lung transplantation. Am J Respir Crit Care Med. 1998;157:288–291.
- Suri HS, Yi ES, Nowakowski GS, et al. Pulmonary Langerhans cell histiocytosis. Orpahent J Rare Dis. 2012;7:16.